![conference banner](/images/conference-banner.jpeg)
Abstract
Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Current Drug Targets
Title:Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Volume: 15 Issue: 2
Author(s): Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. Macaulay
Affiliation:
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Abstract: Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Export Options
About this article
Cite this article as:
Bain Jonathan, Oyler R. Douglas, Smyth S. Susan and Macaulay E. Tracy, Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism, Current Drug Targets 2014; 15 (2) . https://dx.doi.org/10.2174/13894501113146660226
DOI https://dx.doi.org/10.2174/13894501113146660226 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry New Drugs for Epidural Analgesia
Current Drug Targets Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Effect of Cabergoline on Cognitive Impairments in Transgenic <i>Drosophila</i> Model of Parkinson’s Disease
Letters in Drug Design & Discovery The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Current Topics in Medicinal Chemistry Current Genomics in Cardiovascular Medicine
Current Genomics Molecular Mechanisms of Diabetes and Atherosclerosis: Role of Adiponectin
Endocrine, Metabolic & Immune Disorders - Drug Targets Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Pharmacological Therapy in Children with Nodal Reentry Tachycardia: When, How and How Long to Treat the Affected Patients
Current Pharmaceutical Design Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties
CNS & Neurological Disorders - Drug Targets Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Editorial [Hot Topic: Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This (Executive Guest Editors: Aldo Pende and Fabrizio Montecucco )]
Current Pharmaceutical Design New Insights into the Long Non-coding RNAs Dependent Modulation of Heart Failure and Cardiac Hypertrophy: From Molecular Function to Diagnosis and Treatment
Current Medicinal Chemistry Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Acute Myocardial Infarction and Cardiogenic Shock Interventional Approach to Management in the Cardiac Catheterization Laboratories
Current Cardiology Reviews Targeting Calmodulin in Reversing Multi Drug Resistance in Cancer Cells
Mini-Reviews in Medicinal Chemistry